Oct 1, 2026, 08:08 UTC
Teijin announced it will return the manufacturing and sales rights for two pharmaceutical products to their licensors in January 2027 upon expiry of the license period, transferring Mucosolvan to Nippon Chemiphar and Laxoberon oral solution 0.75% to another licensor.
Source:Sep 29, 2026, 20:00 UTC
Teijin and Asahi Kasei will launch a joint textile trading company, TA Frontier, on October 1, integrating their textile trading subsidiaries.
Source:Sep 9, 2026, 10:08 UTC
Shinshu University Hospital, Teijin, and Teijin Regenet announced a joint research agreement in cell and gene therapy drugs on September 9, 2026.
Source:Aug 19, 2026, 04:10 UTC
Teijin announced it has signed a technology advisory contract with Professor Dario Campana of the National University of Singapore to enhance its regenerative medicine CDMO business.
Source: